NUVB PE Ratio & Valuation,Is NUVB Overvalued

NUVB Relative Valuation

NUVB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NUVB is overvalued; if below, it's undervalued.

Historical Valuation

Nuvation Bio Inc (NUVB) is now in the Fair zone, suggesting that its current forward PS ratio of 18.77 is considered Fairly compared with the five-year average of -8.89. The fair price of Nuvation Bio Inc (NUVB) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：8.51

Fair

-14.89

0.00

EV/EBITDA

Nuvation Bio Inc. (NUVB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-15.57

EV/EBIT

Nuvation Bio Inc. (NUVB) has a current EV/EBIT of -15.57. The 5-year average EV/EBIT is -3.38. The thresholds are as follows: Strongly Undervalued below -17.71, Undervalued between -17.71 and -10.55, Fairly Valued between 3.79 and -10.55, Overvalued between 3.79 and 10.96, and Strongly Overvalued above 10.96. The current Forward EV/EBIT of -15.57 falls within the Undervalued range.

18.77

Nuvation Bio Inc. (NUVB) has a current PS of 18.77. The 5-year average PS is 45.51. The thresholds are as follows: Strongly Undervalued below -323.51, Undervalued between -323.51 and -139.00, Fairly Valued between 230.01 and -139.00, Overvalued between 230.01 and 414.52, and Strongly Overvalued above 414.52. The current Forward PS of 18.77 falls within the Historic Trend Line -Fairly Valued range.

-15.09

P/OCF

Nuvation Bio Inc. (NUVB) has a current P/OCF of -15.09. The 5-year average P/OCF is -9.33. The thresholds are as follows: Strongly Undervalued below -25.95, Undervalued between -25.95 and -17.64, Fairly Valued between -1.02 and -17.64, Overvalued between -1.02 and 7.29, and Strongly Overvalued above 7.29. The current Forward P/OCF of -15.09 falls within the Historic Trend Line -Fairly Valued range.

-19.78

P/FCF

Nuvation Bio Inc. (NUVB) has a current P/FCF of -19.78. The 5-year average P/FCF is -9.19. The thresholds are as follows: Strongly Undervalued below -46.52, Undervalued between -46.52 and -27.85, Fairly Valued between 9.48 and -27.85, Overvalued between 9.48 and 28.14, and Strongly Overvalued above 28.14. The current Forward P/FCF of -19.78 falls within the Historic Trend Line -Fairly Valued range.

Nuvation Bio Inc (NUVB) has a current Price-to-Book (P/B) ratio of 8.83. Compared to its 3-year average P/B ratio of 1.65 , the current P/B ratio is approximately 433.99% higher. Relative to its 5-year average P/B ratio of 2.00, the current P/B ratio is about 340.40% higher. Nuvation Bio Inc (NUVB) has a Forward Free Cash Flow (FCF) yield of approximately -6.58%. Compared to its 3-year average FCF yield of -17.34%, the current FCF yield is approximately -62.04% lower. Relative to its 5-year average FCF yield of -13.76% , the current FCF yield is about -52.15% lower.

8.95

P/B

Median3y

1.65

Median5y

2.00

-6.58

FCF Yield

Median3y

-17.34

Median5y

-13.76

Competitors Valuation Multiple

The average P/S ratio for NUVB's competitors is 0.00, providing a benchmark for relative valuation. Nuvation Bio Inc Corp (NUVB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 1704.68%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NUVB increased by 219.92% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 727.00K to 13.12M.

The secondary factor is the Margin Expansion, contributed -92.50%to the performance.

Overall, the performance of NUVB in the past 1 year is driven by Revenue Growth. Which is more sustainable.

1704.68%

727.00K → 13.12M

Revenue Growth

-92.50%

-5.67K → -425.24

Margin Expansion

-1392.26%

1.03 → -13.29

P/E Change

219.92%

2.66 → 8.51

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Nuvation Bio Inc (NUVB) currently overvalued or undervalued?

What is Nuvation Bio Inc (NUVB) fair value?

NUVB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nuvation Bio Inc (NUVB) is between to according to relative valuation methord.

How does NUVB's valuation metrics compare to the industry average?

What is the current P/B ratio for Nuvation Bio Inc (NUVB) as of Dec 16 2025?

As of Dec 16 2025, Nuvation Bio Inc (NUVB) has a P/B ratio of 8.83. This indicates that the market values NUVB at 8.83 times its book value.

What is the current FCF Yield for Nuvation Bio Inc (NUVB) as of Dec 16 2025?

As of Dec 16 2025, Nuvation Bio Inc (NUVB) has a FCF Yield of -6.58%. This means that for every dollar of Nuvation Bio Inc’s market capitalization, the company generates -6.58 cents in free cash flow.

What is the current Forward P/E ratio for Nuvation Bio Inc (NUVB) as of Dec 16 2025?

As of Dec 16 2025, Nuvation Bio Inc (NUVB) has a Forward P/E ratio of -14.69. This means the market is willing to pay $-14.69 for every dollar of Nuvation Bio Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Nuvation Bio Inc (NUVB) as of Dec 16 2025?

As of Dec 16 2025, Nuvation Bio Inc (NUVB) has a Forward P/S ratio of 18.77. This means the market is valuing NUVB at $18.77 for every dollar of expected revenue over the next 12 months.

NUVB Valuation